Published in:

Open Access 01-01-2019 | Correction

Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)

Authors: Maria J. G. T. Vehreschild, Surabhi Taori, Simon D. Goldenberg, Florian Thalhammer, Emilio Bouza, Joop van Oene, Graham Wetherill, Areti Georgopali

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 1/2019